Though insulin-resistance-related hyperinsulinemia and DM-related chronic inflammation promote HCC development, specific DM-associated mechanisms, including reduction of hepatic glycolysis and impairment of insulin hypersecretion, may exert anti-tumor effects in sorafenib-treated HCC. This evidence concerns the gene INS and diabetes mellitus.